Sentences with phrase «b cell target»

For example, multiple mAbs and fusion proteins all take aim at CD20, the B cell target that rituximab first homed in on.

Not exact matches

DPX - RSV is a small, B - cell epitope peptide vaccine targeting the unmet medical needs in respiratory syncytial virus (RSV).

The protein has long been considered too complex to target with a drug as it also is crucial to proper function of many immune system cells, not just B cells gone bad.

«Injecting the human blood cells resulted in massive liver cell damage and we were able to detect cytotoxic T lymphocytes that specifically targeted hepatitis B virus in liver infiltration cells.

«So there has been a lot of interest in the diabetes research community: If you can target those antigen - presenting B - cells, that could be potentially a very effective disease intervention,» says JAX Professor David Serreze, Ph.D., lead author of a highlighted study published in the Journal of Immunology.

They found that hepatitis in these «human hepatocyte chimeric mice» was caused by white blood cells known as cytotoxic T lymphocytes (CTLs) that were specifically targeted to hepatitis B virus.

The target Porter and June ultimately chose was CD19, a protein on the surface of B cells only, discovered by researchers at Harvard Medical School in the 1980s.

This group's achievement reverses the conventional wisdom that memory B cells are induced by high - affinity cells, possibly greatly influencing vaccine strategies targeting memory B cells.

The targeted therapy everolimus may be safely combined with R - CHOP for new, untreated diffuse large B - cell lymphoma according to the results of a pilot study by Mayo Clinic researchers published in the Lancet Haematology.

Bach2, an important gene for inducing memory B cells, may become an important target in vaccine strategies.

The target for ibrutinib, an enzyme called Bruton's tyrosine kinase (BTK), is a key component of B - cell receptor signaling.

This clinical trial sponsored by Juno Therapeutics is testing JCAR017, which targets the CD19 protein expressed on most B - cell leukemias and lymphomas.

In PLAT - 02, the CAR T cells are reprogrammed to recognize and target the CD19 protein that is expressed by most precursor B acute lymphoblastic leukemia cells.

As with innate immunity, the adaptive immune system — the T cells and antibodies produced by B cells that target specific molecules on invading cells — contributes to pathology or may also fight against it.

ABT - 737 targets proteins known as B - cell lymphoma 2 (Bcl - 2) and Bcl - xL, which prevent apoptosis, a form of cell suicide, in cancer cells.

Deletion or targeted inactivation of Cbl - b efficiently enhanced the anti-tumor function of NK cells.

But only after engaging the target and adjusting their antigen receptors over many generations (as B cells do by mutating their antigen receptor genes) can this lineage of cells produce VRC26 bnAbs.

A person's initial pool of B cells — the cells that produce antibodies — may include some that bind weakly to the same V2 apex target on HIV.

It targets the CD52 glycoproteins on the surface of mature immune cells, or lymphocytes, depleting levels of the aggressive T and B cells without affecting other lymphocytes.

Wilson says the process traditionally has taken so long that by the time enough new B cells were generated, the flu strain targeted already had mutated into a form no longer vulnerable to the captured crop of antibodies.

«If you have a spontaneous disease, you have only a short window of time where you can get [ASCs],» he says, «so targeting memory B cells [from someone who has beaten the illness] may be an advantage.»

Called tarocin A and tarocin B, these compounds target a different part of a bacterium's cell wall, called teichoic acid.

CAAR - T cells may provide an effective and universal strategy for specific targeting of autoreactive B cells in antibody - mediated autoimmune disease.

When given to diseased mice, the engineered T cells targeted and killed B cells that express antibodies targeting desmoglein 3, hinting that such a strategy may be an effective way to treat antibody - driven autoimmune diseases.

Whereas traditional MS medications target the immune system's T - cells, ocrelizumab focuses on destroying the system's B - cells, which fuel the brain inflammation that causes the disease to worsen.

«It's not yet clear whether or how GSK3 might be a target for future therapies for B cell - related diseases, but this research opens a lot of doors for further studies,» Rickert said.

The modified T cells contain a protein known as a chimeric antigen receptor (CAR), which is designed to target the CD19 protein found on the surface of B cells, including the cancerous B cells that characterize several types of leukemia and lymphoma.

«We thought we could adapt this technology that's really good at killing all B cells in the body to target specifically the B cells that make antibodies that cause autoimmune disease,» said Milone.

Rituximab is itself an antibody designed to target and destroy B cells.

The artificial receptor acts as a lure for the B cells that target Dsg3, bringing them into fatal contact with the therapeutic T cells.

The auto - reactive B cells produced autoantibodies that mistakenly targeted proteins within their own body, in particular targeting immune inflammatory molecules called interferons and interleukins.

B cell signaling pathways are the current targets of several therapies used to treat B cell malignancies such as CLL.

«An important translational implication of this research is that we hope that by combining Notch inhibitors with drugs that target B - cell signaling we can better treat these B - cell cancers,» said senior author Warren Pear, MD, PhD, a professor of Pathology and Laboratory Medicine at Penn Medicine.

About two decades ago, Lerner's laboratory developed some of the first techniques for using B - cell gene - mixing to generate very large «libraries» of antibodies and swiftly determine which of these can bind to a desired target.

P, Schiroli G, Escobar G, Di Tomaso T, Firrito C, Calabria A, Moi D, Mazzieri R, Bonini C, Holmes MC, Gregory PD, van der Burg M, Gentner B, Montini E, Lombardo A, Naldini L. Targeted genome editing in human repopulating hematopoietic stem cells.

Targeting IFN - alpha to B cell lymphoma by a tumor - specific antibody elicits potent antitumor activities.

A CAR is a protein composed of an antibody that can bind to a known target — in our model we picked the CD19 antigen found on B cell leukemias.

Locafaro G *, Andolfi G *, Russo F, Camisa B, Ciceri F, Bondanza A, Roncarolo MG *, Gregori S. HLA class I - dependent targeting of myeloid leukemia by IL -10-engineered human CD4 + Tr1 cells.

Perforin pores in the endosomal membrane trigger the release of endocytosed granzyme B into the cytosol of target cells.

Cbl - b, a RING - type E3 ubiquitin ligase, targets phosphatidylinositol 3 - kinase for ubiquitination in T cells.

Our data suggests that targeting DGKζ could prove to be a more useful clinical approach to augment cytotoxic T cell activity against tumor than targeting Cbl - b, perhaps resulting from enhanced Ras / ERK signaling.

Scope: 22 institutions Treatment: CD19 - targeting CAR T - cell therapy Results: 42 % of patients with aggressive large B - cell lymphoma remained in remission after 15 months

Potential treatments being studied include training the body to better tolerate myelin, drugs that target the immune system's B cells, blocking proteins that cause inflammation in the body, or even «rebooting» the entire immune system.

Recently, interest has developed regarding the possibility of targeting intracellular inhibitory proteins to improve T cell activity against cancer, including diacylglycerol kinase ζ (DGKζ)(9, 10) and Casitas b - lineage proto - oncogene b (Cbl - b)(11), which attenuate signal transduction events downstream of the TCR and CD28.

CD20 also serves as a useful target for antibody - mediated therapeutic depletion of B cells.

NEMO / IKK: Targeting the interaction between NEMO and IKK to block pathological NF - kB signaling has many therapeutic applications in inflammatory and autoimmune diseases (RA, IBD, psoriasis, acute inflammatory indications, etc.) and oncology (immuno - oncology, B - cell lymphomas, and solid tumors).

CAR T - cell therapy targeting B - cell maturation protein may be a new effective type of immunotherapy treatment for patients with multiple myeloma.

CD22 - targeted CAR T cells induce remission in B - ALL that is naive or resistant to CD19 - targeted CAR immunotherapy.

First observed in B - cell lymphoma, recurrent mutations of epigenetic modifier genes have recently been identified in PTCL - NOS. 9 In the present study, we performed targeted sequencing of the main epigenetic modifier genes in a large cohort of Chinese PTCL - NOS patients.

Moreover, we found that expression of a constitutively active TAZ S89A mutant in ABL1 / ABL2 knockdown breast cancer cells (1833 and SCP28) restored the abundance of its target AXL (Fig. 7, B and C).